Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs TG Therapeutics Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.36 (market cap $77.43B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 9.5× TG Therapeutics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and TG Therapeutics Inc for 16 Days on average.
| MDLZ | TGTX | |
|---|---|---|
Market Cap | $77.43B | $8.16B |
Volume | 7,695,104 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $59.06 |
52-Week Low | $51.51 | $26.94 |
Typical Hold Time | 107 Days | 16 Days |
Enterprise Value | $97.78B | $8.37B |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.41, up 1.73% with a bullish technical signal. The company shows strong fundamentals with consistent earnings beats, $38.54B in 2025 revenue, and improving cash flow. Analyst consensus is strongly bullish with a $70.29 price target. Recent developments include a dividend increase to $0.52 and new product launches like Toblerone Diamond Truffles.
MDLZ presents a compelling investment case with solid profitability (8.86% net margin), attractive valuation (P/E 22.22), and strong analyst support. Key risks include cocoa cost pressures and competitive threats. The stock offers upside potential to consensus targets while providing defensive characteristics in volatile markets.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
